The primary objective of this trial is to evaluate the pharmacokinetics (PK) of two evolocumab drug products in healthy participants.
Male or female, of any race, between 18 and 60 years of age, inclusive.
Body mass index (BMI) between 18.0 and 32.0 kg/m² inclusive.
LDL-C level ≥ 70 mg/dL (1.8 mmol/L) and ≤ 190 mg/dL (4.9 mmol/L) at screening.
History or evidence of any clinically significant disorder, condition, or disease that in the opinion of the investigator (or designee) would pose a risk to participant safety or interfere with the trial evaluation, procedures, or completion.
History or current signs or symptoms of cardiovascular disease.
History or evidence of clinically significant arrhythmia.
History of hypersensitivity, intolerance, or allergy to evolocumab or its ingredients or other biological drugs.